Hey guys,
We need to think about this as a hypothetical assuming we are owners of the company via an investment. Therefore, without any regulatory restrictions, what could/would we do to help our company be successful in NYS. We’d just need to layout the approach that we’d take on how we’d help try and get to a satisfactory result for this particular use case. We would not have to do anything at this point.
Best,
Neil
Neil Callahan
Rosemont Seneca Partners
401 Greenwich Street, Suite 400
New York, New York 10013
212-796-4037 (o)
917-945-9516 (m)
866-749-8879 (f)
Confidentiality Warning: This e-mail contains information intended only for the use of the individual or entity named above. If the reader of this e-mail is not the intended recipient or the employee or agent responsible for delivering it to the intended recipient, any dissemination, publication or copying of this e-mail is strictly prohibited. The sender does not accept any responsibility for any loss, disruption or damage to your data or computer system that may occur while using data contained in, or transmitted with, this e-mail.If you have received this e-mail in error, please immediately notify us by return e-mail. Thank you
From: Eric Schwerin [mailto:eschwerin@rosemontseneca.com]
Sent: Friday, November 04, 2011 9:29 AM
To: abusch@rosemontseneca.com
Cc: John DeLoche; Hunter Biden; Devon Archer; Rob Walker; Neil Callahan
Subject: Re: Input needed
Yes, unfortunately, Hunter, Rob and I are all in the air for much of the day today. That said, my initial thoughts are that this would be a heavy lift for us. I did a quick google search on Dr. Shah there were no immediate avenues to him that became apparent based on his bio and prior experience. I also don't think any of us have any expertise in the NY approval process or know whether getting in front of him would even be helpful. I think we'd need to make a few phone calls and see what we can learn about this. That said, let us think more about it and John maybe I can call you a little later this afternoon between flights.
Eric D. Schwerin
Rosemont Seneca Partners, LLC
1010 Wisconsin Ave., NW
Suite 705
Washington, DC 20007
(202) 333-1880
P Consider the environment before printing this email.
On Nov 4, 2011, at 9:04 AM, Arlene Busch wrote:
John,
Hunter, Eric, and I am all out of the office today traveling. I can't speak for the two of them, but I can not do a call today. I am available on Monday.
Arlene
Arlene Busch
202-333-1880
Abusch@rosemontseneca.com
From: John DeLoche <jdeloche@rosemontseneca.com>
Date: Thu, 3 Nov 2011 20:28:12 -0700
To: Hunter Biden<hbiden@rosemontseneca.com>; Devon Archer<darcher@rosemontcapital.com>; Eric Schwerin<eschwerin@rosemontseneca.com>; Rob Walker<rwalker@rosemontseneca.com>; Arlene Busch<abusch@rosemontseneca.com>; Neil Callahan<ncallahan@rosemontseneca.com>
Subject: Input needed
Hi All,
Founder's Fund completed its $12mm investment in Counsyl today.
I had a call with Counsyl management this evening and they asked if we could be helpful with regulatory channels in NY. Specifically, their lab and test have been approved in 49 states at this point and their lab has been approved by the State of New York, however the test itself is still in in the approval process in NY. NY and CA are two states which require separate lab approval and individual test approval. Counsyl has been told that NY's genetic test approval timing is currently as long as 12 months given current backlog. Specifically, they want us to help them with a roadmap for who we would help them contact at the NY State government level that could help them with this process. One idea discussed, which may or may not be the right one, would be to see if we can get them in front of or on a call with Dr. Nirav Shah, a Governor Cuomo appointee, who is the Commissioner for the NY State Sept of Health. The message would be that Counyl's test is the highest standard of care for expecting parents and it is currently approved in 49 states but not New York.
I'd appreciate it if we could have a call to discuss. They are looking for high level feedback, and potentially a call with us on this subject, by Monday.
Thanks,
John
--
John DeLoche
Managing Director
Rosemont Seneca Technology Partners
One Market, Spear Tower, 36th Floor
San Francisco, CA 94105
office: 415 293 8147
mobile: 415 793 7070
This email communication is privileged and confidential and is intended only for the individuals or entities named above. Any unauthorized dissemination of any of the contents of this email is strictly prohibited. If you are not the intended recipient, please do not read, copy, use or disclose to others the contents of this communication. Please notify the sender that you have received this e-mail in error and then delete the e-mail.